Induction of platelet-derived growth factor and its receptors in acute renal allograft rejection. 2001

J Savikko, and E A Kallio, and E von Willebrand
Transplantation Laboratory, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D010982 Platelet-Derived Growth Factor Mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. Platelet Derived Growth Factor,Factor, Platelet-Derived Growth,Growth Factor, Platelet-Derived
D011920 Rats, Inbred WF An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Wistar Furth,Rats, Wistar Furth,Rats, WF,Inbred WF Rat,Inbred WF Rats,Rat, Inbred WF,Rat, WF,WF Rat,WF Rat, Inbred,WF Rats,WF Rats, Inbred,Wistar Furth Rats
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D017479 Receptors, Platelet-Derived Growth Factor Specific receptors on cell membranes that react with PLATELET-DERIVED GROWTH FACTOR, its analogs, or antagonists. The alpha PDGF receptor (RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA) and the beta PDGF receptor (RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA) are the two principle types of PDGF receptors. Activation of the protein-tyrosine kinase activity of the receptors occurs by ligand-induced dimerization or heterodimerization of PDGF receptor types. PDGF Receptors,Platelet-Derived Growth Factor Receptors,Receptors, PDGF,PDGF Receptor,Platelet-Derived Growth Factor Receptor,Platelet Derived Growth Factor Receptor,Platelet Derived Growth Factor Receptors,Receptor, PDGF,Receptors, Platelet Derived Growth Factor

Related Publications

J Savikko, and E A Kallio, and E von Willebrand
January 1991, Journal of lipid mediators,
J Savikko, and E A Kallio, and E von Willebrand
January 2001, Transplantation proceedings,
J Savikko, and E A Kallio, and E von Willebrand
March 2008, Annals of clinical biochemistry,
J Savikko, and E A Kallio, and E von Willebrand
December 2006, Transplantation proceedings,
J Savikko, and E A Kallio, and E von Willebrand
October 1994, Kidney international,
J Savikko, and E A Kallio, and E von Willebrand
November 1997, Laboratory investigation; a journal of technical methods and pathology,
J Savikko, and E A Kallio, and E von Willebrand
July 1974, Transplantation,
J Savikko, and E A Kallio, and E von Willebrand
May 2000, Annals of surgery,
J Savikko, and E A Kallio, and E von Willebrand
January 1990, Ciba Foundation symposium,
Copied contents to your clipboard!